Implantica
Tracked across 2 events · 22 articles · First seen Aug 14, 2026 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Implantica AG (publ), a medtech company listed on Nasdaq First North Premier Growth Market, announced that it will publish its interim report for the second quarter of 2026 on August 21, 2026, at 8:00 a.m.…
Impact: Implantica is the company hosting the Q2 2026 earnings presentation. The event provides an opportunity for the company to communicate its financial results and strategic progress to investors.
Aug 14, 2026 · 6 articles
Regulatory
Implantica AG, a Liechtenstein-based medtech company, announced on August 20-21, 2026, that the U.S. United States — Food and Drug Administration (FDA) granted Premarket Approval (PMA) for RefluxStop, its implant-based treatment for gastroesophageal reflux disease…
Impact: Implantica received FDA approval for its lead product RefluxStop, enabling U.S. market entry and representing a transformational milestone. This approval is expected to drive substantial commercial growth and positively impact the company's financial performance.
Aug 20, 2026 · 16 articles
100
United States — Food and Drug Administration granted premarket approval ImplanticaFDA approves Implantica...
80
Implantica reportedFDA approves Implantica...
70
Implantica expanded United StatesFDA approves Implantica...
50
Implantica expanded SpainFDA approves Implantica...
ERGEN INTELLIGENCE
Track Implantica live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard